drugset
drugset / Trial / NCT04955678

A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia

NCT04955678 ↗

Phase 3 Completed 85 enrolled Zeria Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the superiority of ZG-801 to placebo in Japanese hyperkalemia patients whose serum potassium value becomes normal in the Run-in period by comparing the change in the value at the Double-blind period week 4, and to further evaluate the efficacy and safety of ZG-801 in Japanese hyperkalemia patients administrated ZG-801 for maximum 9 weeks.

Timeline

Start
2021-08-03
Primary completion
2022-12-26
Completion
2023-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG-801 Unknown — —

Indications

No indication recorded.